VIDEO: Alphyn's AB-101a shows ‘market-leading’ results in atopic dermatitis
Click Here to Manage Email Alerts
SAN DIEGO — In this Healio video perspective from the American Academy of Dermatology Annual Meeting, Alphyn Biologics CEO Neal Koller discusses new data from the company’s phase 2a trial of AB-101a for the treatment of atopic dermatitis.
“The results of this trial are market-leading for the key problems of itch, quality of life and safety,” Koller told Healio.
AB-101a (zabalafin hydrogel) is a novel, first-in-class, multi-target therapeutic natural drug. It treats both the inflammation component and bacterial component of atopic dermatitis, according to Koller.
“The bacterial component has two pieces: infected atopic dermatitis skin, which you have to treat and clear before you can clear the atopic dermatitis itself, and staph bacteria-driven atopic dermatitis flare,” he said. “In both cases, we knocked out the infection in atopic dermatitis skin and demonstrated control of the atopic dermatitis flares through the entire trial.”
Collapse
Healio Interviews
Read more about
Click Here to Manage Email Alerts